Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data

LUND, Sweden, Oct. 17, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in...

Related Keywords

Sweden ,Uppsala ,Uppsala Lan ,Stockholm ,United States ,American ,Hansa Biopharmahansa Biopharma ,Tomas Lorant ,Los Angeles ,Hansa Biopharma ,Prnewswire Hansa Biopharma ,Stanley Jordan ,Klaus Sindahl ,Stephanie Kenney ,Hmedides Clinical Trial Program ,Uppsala University Hospital ,Sinai Medical Center ,American Kidney Fund ,European Union ,European Medicines Agency ,Nasdaq Stockholm ,American Journal ,Associate Professor ,Transplant Surgery ,Transplant Immunology ,Cedars Sinai Medical Center ,Human Leukocyte Antigens ,Investor Relationsm ,Corporate Affairsm ,Priority Medicines ,Ides Clinical Trial Program ,End Stage Renal Disease ,Product Characteristics ,All About ,Dial Transplant ,Englj Med ,